InfuSystem director granted 24,890 stock options

InfuSystem Holdings, Inc. director John J. Sviokla reported an equity compensation grant and his current shareholdings.

Accepted by SEC EDGAR 05/14/2026 - 06:32 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

InfuSystem Holdings, Inc. director John J. Sviokla reported an equity compensation grant and his current shareholdings. He received stock options covering 24,890 shares of common stock at an exercise price of $8.37 per share. These options vest on May 12, 2027 and expire on May 12, 2036, giving him the right to buy shares in the future if conditions are met. The filing also shows he directly holds 10,000 shares of InfuSystem common stock following these transactions.

Insider Trade Summary

Grant/Award: 24,890 shares

Grant/Award 1 txn

Insider SVIOKLA JOHN J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	24,890	$0.00	$0.00
Holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 24,890 contracts (Direct); Common Stock — 10,000 shares (Direct)

Footnotes (1)

1. F1. The option, representing the right to purchase 24,890 shares of InfuSystem Holdings, Inc. common stock, vests on May 12, 2027.

Key Figures

Stock options granted: 24,890 options Exercise price: $8.37/share Options vesting date: May 12, 2027 +2 more

5 metrics

Stock options granted 24,890 options Grant of options on May 12, 2026

Exercise price $8.37/share Exercise price for 24,890 options

Options vesting date May 12, 2027 Vesting date for 24,890 options

Options expiration date May 12, 2036 Expiration for 24,890 options

Shares held after transaction 10,000 shares Common stock directly held following transactions

Key Terms

Stock Option (right to buy), exercise price, vests, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "8.3700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests financial

"The option ... vests on May 12, 2027."

expiration date financial

"expiration_date: "2036-05-12T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did InfuSystem (INFU) director John J. Sviokla report?

John J. Sviokla reported receiving a stock option grant for 24,890 InfuSystem shares. The award is a compensation-related grant, not an open-market purchase, giving him the right to buy shares at a set price in the future.

How many InfuSystem (INFU) stock options were granted to John J. Sviokla?

He was granted options for 24,890 shares of InfuSystem common stock. These options allow him to buy that number of shares at a fixed exercise price if they vest and he chooses to exercise them later.

What is the exercise price and term of John J. Sviokla’s InfuSystem (INFU) options?

The options have an exercise price of $8.37 per share and expire on May 12, 2036. This means he can purchase shares at $8.37 any time after vesting until that expiration date, subject to plan terms.

When do John J. Sviokla’s InfuSystem (INFU) stock options vest?

The stock options vest on May 12, 2027. Vesting means he must wait until that date before he can exercise the options to buy InfuSystem common shares at the agreed exercise price.

How many InfuSystem (INFU) shares does John J. Sviokla hold after this Form 4?

Following the reported transactions, he directly holds 10,000 shares of InfuSystem common stock. This share count is separate from his 24,890 stock options, which are rights to buy additional shares in the future.

Is John J. Sviokla’s InfuSystem (INFU) Form 4 a market buy or a compensation grant?

The Form 4 reflects a compensation grant, not a market purchase. He received stock options classified as a grant or award, giving him rights to acquire 24,890 shares at a fixed exercise price rather than buying shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SVIOKLA JOHN J

(Last) (First) (Middle)

C/O INFUSYSTEM HOLDINGS, INC.

3851 WEST HAMLIN ROAD

(Street)

ROCHESTER HILLS MICHIGAN 48309

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
InfuSystem Holdings, Inc [ INFU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.37	05/12/2026		A		24,890		05/12/2027(1)	05/12/2036	Common Stock	24,890	$0	24,890	D

Explanation of Responses:

1. The option, representing the right to purchase 24,890 shares of InfuSystem Holdings, Inc. common stock, vests on May 12, 2027.

Remarks:

	/s/ Kevin Whitman, Attorney-in-Fact for John J. Sviokla	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)